Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Overexpression and ELISA-based detection of asprosin in cultured cells and mice

Producción científica: Articlerevisión exhaustiva

3 Citas (Scopus)

Resumen

The unreliability of commercial recombinant asprosin preparations and variability between asprosin detection assays have proven to be a bottleneck in experimental interpretation. This protocol describes the use of viral vectors and expression plasmid for overexpression and secretion of human asprosin to achieve sustained elevation of asprosin protein in mice and HEK293T cells without using recombinant proteins. This protocol also includes a sandwich ELISA using anti-asprosin monoclonal antibodies for detection of asprosin in media from cultured cells and in plasma of mice. For complete details on the use and execution of this protocol, please refer to Duerrschmid et al. (2017), Mishra et al. (2021), and Mishra et al. (2022).

Idioma originalEnglish
Número de artículo101762
PublicaciónSTAR Protocols
Volumen3
N.º4
DOI
EstadoPublished - dic 16 2022

Nota bibliográfica

Publisher Copyright:
© 2022 The Author(s)

Financiación

This work was supported by the NIDDK ( DK102529 , DK118290 ). We thank members of the Chopra lab for helpful suggestions and critical reading of the manuscript. We thank Zhiqiang An for rabbit monoclonal anti-asprosin antibody development. Summary figure created using Biorender.com . This work was supported by the NIDDK (DK102529, DK118290). We thank members of the Chopra lab for helpful suggestions and critical reading of the manuscript. We thank Zhiqiang An for rabbit monoclonal anti-asprosin antibody development. Summary figure created using Biorender.com. Investigation, methodology, and writing, I.M.; conceptualization, resources, supervision, funding acquisition, and writing – review and editing, A.R.C. A.R.C. has been awarded asprosin-related patents and is a co-founder, director, and officer of Vizigen, Inc. and Aceragen, Inc. and holds equity in both companies.

FinanciadoresNúmero del financiador
A.R.C. A.R.C.
National Institute of Diabetes and Digestive and Kidney DiseasesDK118290, DK102529
National Institute of Diabetes and Digestive and Kidney Diseases

    ASJC Scopus subject areas

    • General Neuroscience
    • General Biochemistry, Genetics and Molecular Biology
    • General Immunology and Microbiology

    Huella

    Profundice en los temas de investigación de 'Overexpression and ELISA-based detection of asprosin in cultured cells and mice'. En conjunto forman una huella única.

    Citar esto